Paxlovid

Paxlovid is an oral treatment for mild to moderate COVID-19 in high-risk patients. It stops the virus from multiplying and helps prevent severe illness when taken early.

Molecule Details :

  • Molecule Name :

    Nirmatrelvir And Ritonavir
  • Innovator :

    PFIZER INC
  • Approval Date :

    25-May-23
  • NCE-1 Date :

    25-May-27
  • NCE Date :

    25-May-28
  • Dosage Form :

    Tablet
  • Strength :

    150MG;100MG; 300MG; 100MG
  • Therapeutic Category :

    Antiviral
  • Revenue ($M) :

    5,716

Year-wise Projected Sales ($M) :

  • 2025 :

    3,916
  • 2026 :

    3,800
  • 2027 :

    3,675
  • 2028 :

    3,526
  • 2029 :

    3,401
  • 2030 :

    3,277
  • 2031 :

    3,147
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?